New York State Teachers Retirement System Decreases Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

New York State Teachers Retirement System reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 8.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 203,341 shares of the medical equipment provider's stock after selling 19,816 shares during the period. New York State Teachers Retirement System owned approximately 0.09% of Hologic worth $14,659,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC boosted its position in shares of Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. Nordea Investment Management AB boosted its holdings in Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after buying an additional 544,889 shares in the last quarter. Swedbank AB grew its position in Hologic by 18.8% during the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider's stock worth $157,788,000 after buying an additional 306,562 shares during the period. JPMorgan Chase & Co. increased its holdings in Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock valued at $110,700,000 after buying an additional 238,222 shares in the last quarter. Finally, Barclays PLC increased its holdings in Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock valued at $58,507,000 after buying an additional 231,578 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HOLX. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They issued a "peer perform" rating on the stock. Raymond James reaffirmed an "outperform" rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada lowered their price objective on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Finally, Leerink Partners cut shares of Hologic from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $85.77.

Hologic Trading Up 0.2 %

HOLX traded up $0.15 during trading on Friday, hitting $64.47. The company's stock had a trading volume of 2,212,653 shares, compared to its average volume of 2,473,213. Hologic, Inc. has a twelve month low of $62.69 and a twelve month high of $84.67. The firm's 50 day moving average price is $69.91 and its 200-day moving average price is $76.61. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market cap of $14.47 billion, a PE ratio of 20.34, a PEG ratio of 2.13 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the company's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.88% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.